At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 460 enrolled
Drug / intervention
PF-06650833 +2 moredrug
Likely dose
PF-06650833 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-WEEK RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, ACTIVE COMPARATOR, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600 (RITLECITINIB) AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH MODERATELY-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
In Brief
A Phase 2 clinical trial evaluating PF-06650833, PF-06651600, and 1 other intervention for Rheumatoid Arthritis. Completed, enrolled 460 participants across 144 sites in 10 countries.
Detailed Summary
Dual objectives of increased efficacy compared to currently available SoC RA drugs and maintaining a favourable benefit - risk relationship.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBulgaria, Canada, Chile, Czechia, Georgia, Hungary, Poland, Slovakia, Spain, Ukraine
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2020
Primary CompletionFeb 2022
TodayJul 2026
First PostedJun 4, 2020
Enrollment StartJul 29, 2020
Primary CompletionFeb 7, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.1 years ago
Interventions
PF-06650833drug
400 mg
PF-06651600drug
100 mg
Tofacitinibdrug
11 mg